Hinova Pharmaceuticals Inc
688302
Company Profile
- Business description- Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests. 
- Contact- No. 5 Keyuan South Road 
 No. 2 and 3, 4th Floor, Building 1, Rongyao Building
 High-tech Zone, Sichuan Province
 Chengdu610041
 CHN- T: +86 2885058465 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Biotechnology - Fiscal Year End- 31 December 2025 - Employees- 174 
Stocks News & Analysis
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,317.20 | 26.50 | -0.28% | 
| CAC 40 | 8,225.63 | 0.15 | -0.00% | 
| DAX 40 | 24,239.89 | 32.10 | 0.13% | 
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% | 
| FTSE 100 | 9,645.62 | 67.05 | 0.70% | 
| HKSE | 26,160.15 | 192.17 | 0.74% | 
| NASDAQ | 23,204.87 | 263.07 | 1.15% | 
| Nikkei 225 | 49,299.65 | 658.04 | 1.35% | 
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% | 
| S&P 500 | 6,791.69 | 53.25 | 0.79% | 
| S&P/ASX 200 | 9,019.00 | 25.20 | -0.28% | 
| SSE Composite Index | 3,950.31 | 27.90 | 0.71% |